New technologies like CRISPR-CAS or mRNA based vaccines require CI teams to constantly screen the market for opportunities and threats. The need for more focused intelligence that is targeted to the company’s strategic plans and faster access to critical information for decision makers has been increasing dramatically: More opportunities can be turned into a competitive advantage and management can avert potential threats before they become problematic. Monitoring early technology development, finding licensing opportunities or acquisition targets as well as quick access to broad clinical trial information and close surveillance of the competition are key disciplines of CI teams in R&D;